ABSTRACT
Sustainability in kidney care is often perceived as requiring trade-offs in clinical quality, yet green nephrology can strengthen clinical excellence by identifying “sweet spots” where improved outcomes and reduced environmental impact align. Organized along the chronic kidney disease (CKD) trajectory, this review highlights opportunities for responsible practice at each stage. Dialysis, the most resource-intensive component of kidney care, finds a sweet spot in reducing redundancy, personalizing treatment, optimizing vascular access, and empowering patients. Approaches such as incremental dialysis, water-efficient systems, and well-planned vascular access improve both clinical and environmental performance. Upstream, CKD prevention remains the most powerful strategy for increasing survival and reducing human and planetary burden. The sweet spot on early diagnosis and optimized CKD care may be identified in shifting away from medication escalation toward lifestyle-focused interventions, deprescribing when appropriate, and reducing treatment burden. Research also plays a critical role, with substantial potential to reduce waste by minimizing redundancy, promoting data sharing, adopting efficient trial designs, and leveraging digital tools. Options that are resource sparing are however usually more time-consuming, thus highlighting the central role of the nephrologists in individualized kidney care. In essence, green nephrology is not “less” care; it is better care, sitting at the intersection where clinical excellence and environmental stewardship reinforce one another.
Keywords: chronic kidney disease, green nephrology, haemodialysis, sustainability
Graphical Abstract
Graphical Abstract.
INTRODUCTION
The concept of green medicine—an evocative term that combines sustainability, equity, and nature—has evolved in the last two decades, in parallel with the acceptance of the importance of changing our attitudes before irreversibly endangering the planet. Nephrology, thanks also to the pioneering work of John Agar and colleagues, was among the first clinical disciplines involved in a paradigm shift from consuming to sparing in care [1].
Dialysis became the initial focal point for this transformation. Although not the most polluting medical therapy, its unique characteristics made its ecological footprint particularly visible [2, 3]. Dialysis is a lifelong treatment for many patients, with substantial requirements for water, energy, consumables, transportation, and waste management. From this starting point, all phases of kidney care, from prevention to kidney transplantation (KT), were embraced, shifting from green dialysis to green nephrology [4, 5].
The measurement of the ecologic impact of care is challenging, and knowledge gaps impair precise quantifications and comparisons. Logically, the life-cycle analysis is indispensable to start the quantification of the ecologic impact of an object and (even more complex) of a procedure (Fig. 1) [6, 7]. However, in a globalized world, extraction of raw materials and the different phases of “making” usually occur in different settings, with wide variability of intermediate phases, such as transportation, or waste disposal. Hence, to cite the iconic book How Bad Are Bananas?, while it is possible to assess the carbon footprint of “almost everything,” this comprehensive measure is based on theoretical averages, that present a very imperfect fit to real-life situations, and have a unsurprisingly large margin of uncertainty [8, 9].
Figure 1:
Life-cycle assessment of a dialysis machine: sources of uncertainty at each stage.
The general concepts of reducing needs, limiting the use of goods and supplies, choosing wisely, recycling whenever possible, and disposing carefully, apply to all healthcare fields. However, we have to be aware of the risks of oversimplification and on the need for contextualization. One example regards peritoneal dialysis. Notwithstanding clinical equivalence, this option is economically sound in Australia or Hong Kong, but carries a huge economic burden in Egypt, where the few existing programs strive to survive, due to the high costs (and carbon footprint) of importing supplies [6, 10].
Hence, limits, knowledge gaps, and uncertainty of measures should be considered when critically exploring the potential axes of action for finding the “sweet spot” as the intersection where clinical excellence, medical progress, and respect for the planet reinforce rather than undermine each other.
There is no reason why excellent patient care should compete with planet stewardship, and vice versa.
This principle underpins the Centre for Sustainable Healthcare’s concept of “sustainable value” defined as patient and population outcomes relative to the environmental, social, and financial costs of providing care [11].
Why, then, is green nephrology so often framed as a compromise, where improving sustainability is assumed to require a reduction in the quality of care, to fulfill the incontrovertible need to reduce the environmental footprint of kidney care?
A similar framework is used beyond nephrology, when it is argued that progress with sustainability will lead to less freedom, wealth, or comfort, needing a trade-off between those aims and the green agenda [12, 13]. Here, we argue that quality and green nephrology can be aligned, provided a change in the current mindset. In this review, we follow the chronic kidney disease (CKD) trajectory “downstream to upstream,” beginning with dialysis, the most demanding component of kidney care, progressing through advanced CKD, early CKD care, and finally CKD prevention. To operationalize the concept of “sweet spots” across this trajectory, we summarize the areas in which clinical excellence and environmental responsibility converge (Table 1) and illustrate the three pillars underpinning this convergence (Fig. 2). This structure reflects our central argument that “sweet spots” between sustainability and clinical excellence exist at every stage of care.
Table 1:
Integrated “sweet-spot” opportunities and trade-offs across the CKD trajectory.
| CKD stage/domain | Intervention | Clinical advantages | Environmental advantages | Trade-offs/evidence gaps |
|---|---|---|---|---|
| Dialysis | Incremental HD/PD | Preserves RKF; fewer hospitalizations | Reduced water/energy use; fewer consumables | Requires monitoring; not suitable for all |
| Dialysis | High-volume hemodiafiltration (HDF) (iso-resource) | Improved survival in select patients | Comparable footprint when optimized | Protocol-dependent; equipment variability |
| Vascular access | First-time-right AV access | Fewer complications and procedures | Avoids procedural waste; lower interventional suite emissions | Needs early referral and coordination |
| Advanced CKD | Deprescribing + lifestyle interventions | Better Quality of life (QoL); fewer side effects | Reduced pharmaceutical production and waste | Time-intensive; absent from guidelines |
| Early CKD | Lifestyle-focused early care | Slower CKD progression; metabolic benefit | Plant-forward diets reduce emissions; fewer meds | Requires patient engagement; workforce limits |
| Prevention | Public health & policy strategies | Reduced CKD and cariovascular disease (CVD) incidence | Largest long-term footprint reduction | Delayed impact; requires societal change |
| Research | Low-redundancy, efficient trial models | Faster evidence generation; better efficiency | Lower footprint—less travel/materials | Complex design; expertise required |
Figure 2:
The sweet spot in green nephrology: convergence of three pillars of sustainable care.
GREEN NEPHROLOGY IS NOT LOW-COST, LOW-INTENSITY NEPHROLOGY
The case of dialysis
The famous three “r” of environmentalism—reduce, reuse, recycle—with the added fourth of “repair” apply naturally to nephrology [14]. In dialysis, the foremost “r”—reduce—applies directly to minimizing redundancy, such as delivering un-needed dialysis sessions, for the sake of an easier management of the dialysis ward, concerns on profit (unused “empty chairs”), or using of high dialysate flows following a consolidated praxis in the absence of proven clinical advantages [15, 16].
It has been calculated that 4–10 tonnes of CO2-equivalent are generated per patient-year, on a standard schedule (hemodialysis, 4 h, thrice weekly). Calculating the carbon footprint of dialysis means summing the effects of water/energy use, materials, waste management, and transportation. As expected, the result range is very broad, according to the setting, type of calculation, and items considered [4]. Recent studies from Spain and Germany highlight that simple measures, including the use of a hemodialysis carbon footprint calculator, could substantially reduce greenhouse gas emissions (∼9% in the multicenter German study). The most effective, ready-to-implement actions included lowering dialysate flow, expanding the use of solar energy, and replacing snacks provided during dialysis with healthier diet options [17, 18]. Dialysis hardware warrant re–evaluation. Recent studies of end of life of hemodialysis machines illustrate that current devices have very limited recycling potential [19]. These findings underline the need to redesign dialysis machines according to cradle–to–cradle principles, to enable meaningful material recovery, aligning device life cycles with sustainability goals.
Personalized dialysis, started upon clinical indications, and adapted to residual kidney function and metabolic needs, may allow for reducing the treatment burden. The choice is patient-friendly, and its “planet-friendly” nature is likewise evident. Safe personalization, in particular when the dialysis dose is lower than the standard “kidney replacement therapy”, however, requires investments in time and controls [20, 21]. While the balance is favorable for the healthcare system and the environment, the concept that personalized dialysis is not merely “less dialysis” should be stressed if its undeniable advantages have to be maintained. Less dialysis, or no dialysis in patients with whom a conservative pathway has been chosen, should remain framed by a policy of avoiding futility, limiting useless interventions, while improving the overall quality of care [22, 23].
A recent meta-analysis of 22 observational studies confirms that an incremental dialysis start does not increase mortality but may lower hospitalizations, preserve residual kidney function, and lead to better patient-centered outcomes [20]. Further studies analyzed the environmental and economic perspective. For instance, Choo et al. described sustainable kidney care practices at Bradford Teaching Hospitals NHS Trust. Incremental/decremental dialysis demonstrated the largest benefit, exceeding all other approaches (like online priming, centralized acid delivery, dialysate autoflow, upgrading water treatment systems, etc.). Twice-weekly hemodialysis resulted in the highest cost savings and the largest reduction in Greenhouse Gases (GHG) emissions (≈30 000 kg CO2-equivalent per year if applied in 25 patients) [21]. Torreggiani et al. showed that, in a large French center, incremental dialysis start (one or two sessions per week) was feasible in about two-thirds of patients, with about half of them remaining on less-frequent schedules for 1 year or more [24].
Incremental peritoneal dialysis represents another strategy, adapted to residual kidney function along with peritoneal clearance characteristics [25]. It has been calculated that one patient on full-schedule peritoneal dialysis generates ∼600 kg of waste annually, with a carbon footprint of 1.2–4.5 tonnes of CO2-equivalent each year [22]. Besides clinical benefits, like reduced glucose exposure, fewer infections, and better quality of life, incremental peritoneal dialysis obviously reduces water usage, plastic waste, and carbon emissions. However, the advantages of incremental strategies are differently quantified; inconsistent definitions highlight the need for uniform reporting.
Hemodiafiltration is relevant in the sphere of green nephrology. Without entering into technical details, offering this dialysis option, that has demonstrated better survival results in randomized studies and meta-analyses, is not necessarily associated with a higher water and carbon footprint. However, once more, its “iso-resource adaptation” needs an investment in time and controls [26, 27].
In its broader meaning, green dialysis also encompasses the principle of equity. Global estimates suggest that ∼4 million of people who need dialysis or transplantation are unable to obtain it. Hence, ensuring access to dialysis is an ethical imperative [28, 29]. However, lower-impact dialysis practices in high-income countries will not, by themselves, translate into increased access to care in low-resource settings. The drivers of limited access—insufficient infrastructure, workforce shortages, political instability, supply-chain vulnerability, and financial constraints—are largely structural and disconnected from efficiencies achieved in wealthier systems.
Nevertheless, sustainability efforts in high-income settings remain relevant globally. They help identify best practices, promote technological innovation, reduce the overall carbon footprint of the sector, and may influence the design of future systems. Importantly, strategies developed in well-resourced health systems—such as water-efficient technologies, renewable-energy integration, and reduction of clinical redundancy—can inform the creation of lower-impact programs when and where new facilities are built. Green nephrology, therefore, cannot claim that responsible practice in one region directly enables access elsewhere, but rather that sustainability principles should accompany expansion of dialysis without replicating low-sustainability models [1, 4, 30].
Reducing intervention redundancy means also empowering patients. Therapeutic adherence, arguably one of the best indicators of responsible resource use, depends on shared decision-making and patients’ empowerment. Life on dialysis is demanding, and when several modalities are available (e.g. peritoneal dialysis, home hemodialysis, satellite-unit dialysis, or in-center care), the ethical principles of equity, justice, and autonomy inevitably intersect [5, 30–32]. Once a modality is chosen, informed patients can meaningfully contribute to improving sustainability of their care pathway. Importantly, a green dialysis perspective should not mean imposing a modality because it is presumed to be “better for the planet.” Rather, sustainability should be integrated into holistic care planning, supporting patients in adopting clinically appropriate and environmentally responsible practices, such as optimizing diet and lifestyle, minimizing unnecessary travel, preventing medication waste, and safely managing treatment-related waste.
The case of dialysis vascular access
Vascular access represents a pivotal domain where clinical quality and environmental stewardship may converge. Well-planned access is associated with reduced complications, hospitalizations, and treatment burden, consequently avoiding further procedures. Each prevented infection, thrombosis, or access failure could be seen as a “green metric,” although rarely highlighted on standard dashboards [33]. A “first-time-right” strategy requires timely referral, modality-aligned shared decision-making, and coordinated input from nephrologists, surgeons, interventionalists, and access nurses. This approach yields fewer bloodstream infections, related to the use of temporary catheters, and fewer unplanned vascular access interventions and hospitalizations [34] curtailing consumption of procedure kits, medications, and imaging and inpatient resources. The environmental implications of procedural burden, including the carbon footprint of interventional radiology suites, which can generate up to 23 500 kg CO2-equivalents over just five weekdays, warrant careful consideration [35]. Along the same line, crash dialysis starts and emergency catheter insertions represent environmental “hotspots” along the CKD trajectory, triggering resource-intensive cascades, such as emergency evaluation, urgent central venous catheter placement, unplanned admission, and high-dose hemodialysis [36]. Conversely, proactive vascular access preparation represents a high–yield strategy not only improving patient outcomes, but also reducing the environmental footprint of dialysis.
The case of kidney transplantation
Detailed in a dedicated paper, in this Special Issue, KT can be considered by itself the sweet spot in kidney replacement therapy, since it associates a superior clinical profile with a better ecologic performance. Cadaveric kidney donation has even been taken as an example of circularity of life, and, even though this has been seen as culturally sensitive in some settings, for instance in the Mediterranean countries the concept of life arising from life has been extensively employed in educational campaigns in favor of kidney donation [57].
Comparing dialysis and KT is not easy. While the advantages in the case of a well-functioning KT are clear and spam from lower blood tests, lower need for transportation, and, of course, lower production of plastic waste, less is known on the ecologic burden of a less-than optimal kidney graft, and comparisons are impaired by the lack of data on the life cycle and carbon footprint of most of the employed drugs [36].
Since KT is well-acknowledged as the best type of kidney replacement therapy, every effort should be addressed to expand its availability, addressing the main barriers of lack of donors in high-income countries and lack of infrastructure in low-medium-income countries. In the context of the excellent combination or quality of care and sustainability, to optimize long-term results in people living with KT, a main clinical focus should be on drug management, avoiding noncompliance, still one of the main causes of KT failure. Controlling the pill burden, with the same caveats described for CKD care, has the double advantage of reducing the carbon footprint of care, and of limiting noncompliance [37]. Attention to dietary management and lifestyle may further enhance the therapeutic advantages.
The case of optimizing advanced CKD care
Identifying the “sweet spot” in advanced CKD care is challenging. Access to both new and established kidney-protective agents remains largely confined to high-income settings and to wealthier individuals in low- and middle-income countries. Treating all eligible CKD patients could generate significant clinical benefits in the medium-long term but would also substantially increase both economic and environmental costs in the short term [42]. The goal—treating everyone who stands to benefit—remains essential, but achieving a sustainable equilibrium requires a shift in mindset. Rather than relying solely on medication escalation, truly optimized CKD care should more efficiently integrate lifestyle modification, dietary counseling, deprescribing where appropriate, and collaborative patient engagement to reduce treatment burden while preserving clinical effectiveness (Fig. 3). Pharmacological and nonpharmacological approaches are allied and complementary.
Figure 3:
How kidney care for all can be balanced with planet care for all: reaching the sweet spot.ger lifespan,
Indeed, the strategy of progressively adding kidney-protective drugs (whose carbon footprint is not fully established) to counteract kidney function impairment is appealing, but may have the side effect of diverting attention from nonpharmacologic actions. Among them, nutritional management, associated with physical activity, does not only have a well-established potential to reduce the progression of CKD, but is also planet-friendly, as elsewhere discussed in this issue [38, 39]. Treatment burden is inversely associated with quality of life in chronic diseases, including kidney failure (KF), and is also inversely proportional to therapeutic adherence, leading to indirect increases in the ecologic burden of care (wasted drugs) [40, 41].
A large body of evidence—including the landmark MDRD (modification of diet in renal disease ) trial—demonstrates that prescribing a diet is insufficient to achieve meaningful lifestyle change [43]. Ultra-processed food is less expensive and often more user-friendly, but is less healthy. The recent Kidney Disease: Improving Global Outcomes guidelines on CKD clearly resume how physical activity goals are met by a small percentage of individuals. Hence, while logically what is attainable without a pharmacologic treatment should come first, the need for more dedicated time to change daily habits favors a drug-based approach potentially leading to the “Prescribing Paradox.” To meet clinical targets, clinicians often prescribe more pills, with frequent side effects and even a worse quality of life, potentially leading to generalized noncompliance [44–46]. Avoiding this paradox is a clear instance where clinical excellence and ecological stewardship converge.
Despite their relevance, deprescribing strategies remain absent from current nephrology guidelines, even though they are well established in geriatric medicine and associated with improved outcomes, better quality of life, and fewer hospital readmissions [46–48]. Deprescribing implies a shift from the “prescription cascade” of more medications leading to more side effects, prompting still more medications. Deprescribing is clinically, ethically, and environmentally sound, but requires time: time to prioritize which therapies are essential, time to discuss changes with patients, and time to build the therapeutic alliance needed to maintain adherence [48, 49].
Empowering patients, one of the Centre for Sustainable Healthcare’s core principles [49], is a crucial component of optimizing advanced CKD care. Effective patient empowerment improves clinical outcomes and reduces healthcare demand by enabling meaningful lifestyle change, supporting adherence, and facilitating early recognition and management of complications. Patient empowerment necessitates good communication, goal setting, patient-accessible health records, structured education, peer support networks, and shared decision-making [50]. While the diffusion of electronic health records facilitates this task, strategies for elderly and culturally fragile individuals (more prone to develop side effects, but with low electronic literacy) should also be undertaken.
While demonstrating the advantages of early kidney care is difficult [51], measuring the negative impact of late referral is feasible and a large body of evidence supports that late nephrology care is associated with poor outcomes [52–54]. Avoiding what has defined “suboptimal predialysis care” [55] with “crash start” of dialysis is clinically and economically sound, and is expected to be also ecologically advantageous. However, no study so-far explored these issues from the point of view of ecologic (carbon footprint) impact.
Expanding high-quality predialysis care cannot rely solely on individual clinicians; it requires rethinking the configuration and capacity of the nephrology workforce in both high- and low-middle-income settings. Strengthening upstream nephrology engagement, with prevention and early diagnosis, and referral in any case before patients reach crisis, is a sweet spot where clinical excellence, health-system efficiency, and environmental stewardship converge.
The case of early diagnosis and early CKD care
Current guidelines generally recommend referral for patients with significant proteinuria or advanced CKD (stages 4–5), thereby restricting nephrologists’ intervention perimeter, limiting interventions when treatments are likely to be most effective. In contrast to this narrow approach, the recent WHO guidance elevates kidney disease as a global health priority and explicitly emphasizes the importance of early diagnosis, particularly in vulnerable populations [56]. The WHO document notes, among others, that kidney disease is both a risk factor for and a consequence of hypertensive disorders of pregnancy, which are linked to maternal mortality, preterm delivery, and low-birth-weight infants who themselves face increased lifetime risk of kidney. This highlights the need for earlier assessment and more proactive kidney care across the life course.
Prevention, early diagnosis, and timely intervention are inherently time–intensive, and workforce limitations remain a major barrier. To date, no studies have examined the carbon footprint associated with clinician time spent in nephrology visits, nor have they compared long–term outcomes when education and counselling are delivered, and, in this latter case, have explored outcome differences when education rests mainly on nephrologists versus generalists or other health professionals [57, 58]. These gaps underscore the need to better understand not only when nephrology care should start, but who is best positioned to deliver it, and how these choices influence both patient outcomes and the environmental impact of kidney care.
Diagnosis of kidney disease in its earliest stages remains challenging. A decline in estimated glomerular filtration rate becomes apparent only after substantial nephron loss—typically >50%—has already occurred. Albuminuria is a sensitive marker of cardiovascular risk, yet it is not consistently present in the early phases of all kidney diseases; for example, children with congenital anomalies of the kidney and urinary tract may have normal albumin excretion. Imaging studies, while fundamental, are time-consuming, operator-dependent, and often insufficient for early detection of common diseases such as nephroangiosclerosis.
A substantial body of evidence indicates that early initiation of established and newer kidney-protective therapies—including angiotensin converting enzuyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Sodium-glucose co-transporter 2 inhibitors (SGLT2) inhibitors, and glucagon-like peptide 1 (GLP-1) receptor agonists—can stabilize kidney function and delay progression for prolonged periods [57, 59, 60].
To maximize the benefits of these therapies, CKD must be identified earlier than it currently is. In Europe, e.g. nearly 30% of individuals who start dialysis have had no prior or only irregular nephrology follow-up, underscoring missed opportunities for timely interventions. Although standardizing referral criteria may improve consistency, rigid thresholds risk overlooking the “sweet spots” where specialist involvement could meaningfully alter disease trajectory [61].
No single model of early CKD care will suit all settings. However, a paradigm that primarily relies on adding medications at predetermined thresholds is not consistent with the principles of sustainable or “green” nephrology. Personalized care requires time: time for counseling, lifestyle guidance, diet optimization, and shared decision-making (Fig. 4) [57]. Shifting from a fast-medicine, drug-intensification model to one centered on education and behavior change is labor-intensive and demands appropriate expertise. How much of this responsibility should rest with nephrologists, and how much can be shared with primary care or other health professionals, remains uncertain, and is probably context sensitive. The optimal configuration depends on local workforce capacity and health-system structure and participation of multiple experts should be balanced against the risk of fragmenting care.
Figure 4:
Personalized, planet-friendly care requires time: drug-based versus education-based approaches. terms of time.
The case of CKD prevention
Prevention appropriately sits at the forefront of discussions on green nephrology, as the most effective way to reduce its clinical, social, and environmental burden. In high-income countries, most CKD and KF cases arise from preventable conditions, such as type 2 diabetes, obesity, hypertension, and cardiovascular diseases [29, 62–64]. Obesity and type 2 diabetes are strictly related to lifestyle and nutrition patterns, and are favored by genetic and environmental factors, including low birth-weight (partly preventable in itself) [65]. In low-resource settings, several kidney diseases, such as Mesoamerican Nephropathy, are linked to environmental exposures and hazardous working conditions and are largely preventable. Achieving this, however, requires substantial societal engagement, regulatory action, and a fundamental shift in occupational and environmental protections [2, 30].
The global rise in the so-called lifestyle-related diseases is not inevitable; rather, it is sustained through wealth inequalities, unhealthy food systems, and low physical activity levels [66, 67]. Addressing lifestyle determinants of health is however complex and important initiatives, such as investing in transport infrastructure to reduce car dependence, or promoting healthy plant-based diets, require sustained efforts and time to yield population-level changes. Nevertheless, some policy actions can achieve rapid public health gains, e.g. through regulation of the food industry.
Prevention should begin early in life, a principle not specific to nephrology. The role of the nephrologists is usually mainly supportive, through communicating the evidence on prevention of kidney diseases to colleagues, policy makers, and the public. Prevention is not always possible: cardiovascular ageing is one of the limiting factors of the lifespan, and prevalence of cardiovascular diseases increases with the ageing of the population. Nephroangiosclerosis is the one of the most common kidney diseases, and is related to vascular impairment. The longer the life spam, the higher its incidence. In this context, prevention becomes synonymous of retarding the clinical onset of severe CKD (and need for kidney replacement therapy) and not of avoiding it absolute terms. Type 2 diabetes provides an example of how competitive mortality reduction leads to an increase in other end-organ damage, including KF, dispelling the claims of the St Vincent Chart that, in 1989, set the ambitious goal of reducing KF incidence by 33% in 5 years by improving diabetes care [68, 69]. The sharp decrease in mortality allowed more individuals with type 2 diabetes to survive, and patients with diabetes now account for 25-over 50% of incident dialysis patients. Hence, even if foreseeing the net effects of prevention is not easy, retarding the clinical onset of CKD has the potential to lead to an absolute reduction in the incidence and duration of KF which has a real impact on resource use needed for dialysis.
The case of research in nephrology
Research is a foundational component of medicine. Although it is resource intensive, it has the potential to drive the development of greener technologies, treatments, and models of care [70]. A first step is identifying redundancy: research activities that consume resources without adding value—such as unnecessary investigations, repetitive studies, or failure to use existing datasets. Improving dissemination practices could prevent costly and unnecessary duplication of experiments, facilitate reproducibility, and promote inclusivity. Research laboratories often use hazardous or nonrecyclable materials [71] and sustainable practices are probably underrepresented and underreported. Sharing of equipment, data, and resources [72] should be promoted to deliver environmental benefit while improving the quality of the evidence [73].
The carbon footprint of clinical trials can be reduced by optimizing trial sites and sample collection, preventing low-value studies, and using approaches like basket and umbrella trials, which evaluate various treatments and conditions concurrently, following also the 2019 National Institute for Health and Care Research recommendations [74, 75]. Furthermore, digital platforms like Epic and Telehealth may support efficient and sustainable science, even if they may increase need for transfers of biological samples and drugs. Among the few available examples, the Nightlife study, one of the few randomized controlled trials evaluating its carbon emissions, reported having lowered the carbon footprint by 136 tonnes of CO2-equivalent with respect to a conventional in-presence approach, via online conferencing, remote work, and virtual interviews [76].
Patients’ view on green nephrology
The role of the patient is fundamental not only in the early stages, but throughout the entire course of care, which, for those of us with CKD, means lifelong care.
The priorities of a patient who has just been diagnosed with a severe chronic illness, such as KF, revolve around their suffering and the limitations that result from it. The immediate goal is to find a way to feel better, despite the new condition.
Clear information makes it possible to choose the treatment pathway that is most appropriate and compatible with one’s lifestyle—whether it involves work, retirement, physical activity, family commitments, and so on. When a patient understands what is happening, adheres better to therapies and becomes responsible and engaged. Compliance arises from knowledge, but also from mutual respect and the relationship of trust that the physician is able to build. An informed patient develops the ability to look beyond the own clinical experience and becomes more aware of the choices. Green dialysis is not only technology: it is also culture, education, and a conscious alliance between those who provide care and those who receive it.
We, Alina (nicknamed Ali, meaning Wings in Italian), and Rossella, in short Ross or Red, selected two examples: for Ross, the transition from three dialysis sessions per week to two. The physician took a strong responsibility at that time, when incremental dialysis was not a common option, of course considering compatible laboratory results. Individual well-being and sustainability were and are the same sweet spot; however, mutual trust is needed for personalization. In 2005, Ali underwent her first dialysis on the same day as diagnosis: hemoglobin was 5 g/dl and creatinine 13 mg/dl. It was an abrupt, sudden entry into an unfamiliar world. Her first kidney transplant, in 2007 lasted almost 10 years. When, in 2016, dialysis was needed again, the situation was different. Ali was prepared: informed, autonomous, aware of her clinical history, her body, her limits, and resources. She recalls: “I expected an ‘incremental’ approach, which would allow me to preserve autonomy and quality of life, adapting to the new changes. My new doctor, however, told me: ‘I am the doctor, I decide what is best for you.’ At that moment, I felt that I was losing my active role in the care process. I replied that the therapeutic choice belonged to me, because no one knows better than the patient the physical and emotional experience of illness. After a heated discussion, I managed to restart with only one dialysis session per week. Then, by carefully monitoring my values and maintaining dialogue with the team, I moved to two, and to three sessions, ultimately at night, to allow continue working. It was a shared path, built step by step. In the end, the entire team embraced my personalized pathway.”
What we claim is nothing more than the right to a free and informed choice. Our experiences may support something every physician should know, but which is sometimes difficult to practice in the current system of care. When patients are informed, listened to, and involved, they become powerful allies. And care, inevitably, works better.
To support dialysis choice, we hold that patients should also be informed about the level of sustainability of their treatments. However, we believe that this vital choice should not be constrained by economic or environmental costs. Overall, patients want personalized care, and prefer “light care,” avoiding overtreatment, minimizing complications. This is also more sustainable. The objectives we have sought to summarize are reported in Box 1.
Box 1.
Objectives by 2030.
Effective yet sustainable treatments, with attention to avoiding unnecessary waste of resources, ensuring coherence between caring for one’s health and respecting the environment.
Greater information to increase environmental awareness, with a focus on waste during dialysis sessions (water, plastic, and single-use materials), because knowing that “green” practices exist increases trust and reassurance.
Patients’ mental well-being—fostering pride and participation in contributing to a more sustainable healthcare system.
Promoting awareness of the convenience of home dialysis, also experienced as an ecological choice in addition to a personal one (e.g. reducing travel to dialysis centers, resulting in less stress and lower environmental impact through reduced CO2 emissions).
Transparent environmental communication: patients appreciate when their dialysis center communicates the sustainable actions it has adopted.
CONCLUSIONS
Green nephrology should not be seen as a constraint but as an opportunity to redefine high–quality kidney care. Across the CKD trajectory, multiple “sweet spots” demonstrate that improved clinical outcomes and reduced environmental impact can be achieved simultaneously, including promotion of KT, incremental-personalized dialysis, first–time–right vascular access, deprescribing with lifestyle–centered advanced CKD care, early CKD management, and upstream prevention. Together, these examples show that environmentally responsible nephrology often mirrors patient–centered, evidence–based practice.
Nevertheless, important gaps remain. The carbon footprint of nephrology, particularly the life–cycle impact of pharmaceuticals and the ecological implications of upstream care, remains insufficiently characterized. Environmental metrics are rarely embedded in clinical practice or research, and deprescribing frameworks are still absent from nephrology guidelines. Addressing these limitations will require methodological innovation, standardized reporting, and integration of sustainability into routine quality–improvement efforts.
Looking ahead, sustainability should become a defining dimension of excellence in kidney care. Achieving this will depend on engaging all stakeholders, redesigning workflows, allocating time for individual patient care and education, and strengthening interdisciplinary collaboration. Green nephrology does not imply a choice between people and planet; rather, it offers a framework in which better clinical outcomes and lower environmental impact reinforce each other. In this sense, sustainable nephrology is not about providing less care, but providing better care, including for the world we inhabit.
Contributor Information
Mariana Murea, Wake Forest University School of Medicine, Winston-Salem, USA.
Frances Mortimer, Centre for Sustainable Healthcare, Oxford, UK.
Gulay Demirtas, Antalya Training and Research Hospital, Antalya, Turkey.
Alina Seman, Freelance patient, Turin, Italy.
Rossella Picillo, Freelance patient, Turin, Italy.
Ilaria de Barbieri, University of Padua, Nursery and Midwifery Science, Padua, Italy.
Alexander Woywodt, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Giorgina B Piccoli, Néphrologie et Dialyse, Centre Hospitalier Le Mans, Le Mans, France.
CONFLICT OF INTEREST STATEMENT
None declared.
REFERENCES
- 1. Barraclough KA, Agar JWM. Green nephrology. Nat Rev Nephrol. 2020;16:257–68. 10.1038/s41581-019-0245-1 [DOI] [PubMed] [Google Scholar]
- 2. Vanholder R, Abdellatif D, dos Santos ACS Jr et al. Kidney health for all: caring for people, protecting the planet. Kidney Int. 2026;109:408–17. PMID: 41722936. 10.1016/j.kint.2025.12.020 [DOI] [PubMed] [Google Scholar]
- 3. Ma O, Mocanu V, Ng C et al. Environmental sustainability in the operating room: perspectives and practice patterns of general surgeons in Canada. Can J Surg. 2026;69:E84–9. PMID: 41708284. 10.1503/cjs.012325 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Barraclough KA, Berman-Parks N, Jha V et al. ; Conference Participants. (February 17, 2026) Green dialysis: environmentally sustainable care, growth, and innovation: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 10.1016/j.kint.2026.01.015. PMID: 41713645. https://doi.org/10.1016/j.kint.2026.01.015 [DOI] [PubMed] [Google Scholar]
- 5. Piccoli GB, Murea M, M BH et al. Sustainable nephrology: state of the art needs for education and implementation. Clin J Am Soc Nephrol. 2025;20:889–901. PMID: 40239046. 10.2215/CJN.0000000731 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. McAlister S, Talbot B, Knight J et al. The carbon footprint of peritoneal dialysis in Australia. J Am Soc Nephrol. 2024;35:1095–103. PMID: 38671537. 10.1681/ASN.0000000000000361 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Grinstein A, Kodra E, Chen S et al. Carbon innumeracy. PLoS One. 2018;13:e0196282. 10.1371/journal.pone.0196282 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Berners-Lee M. How Bad Are Bananas?: The Carbon Footprint of Everything. Revised edition. London: Profile Books Ltd, 2021, ISBN: 9781788163811 eISBN: 978-1782837114. [Google Scholar]
- 9. Woods R, Masthoff J. A comparison of car driving, public transport and cycling experiences in three European cities. Transp Res A: Policy Pract. 2017;103:211–22. ISSN 0965-8564. [Google Scholar]
- 10. Darwish R, Brown E. Global perspective on challenges and potential solutions to increasing peritoneal dialysis in Egypt. Kidney360. 2024;5:1913–6. 10.34067/KID.0000000595 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Centre for Sustainable Healthcare . Leading a Sustainable Transformation in Healthcare. https://sustainablehealthcare.org.uk/ (25 February 2026, date last accessed).
- 12. Putnis N, Neilson M. Environmental sustainability and quality care: not one without the other. Int J Qual Health Care. 2022;34:mzac066. 10.1093/intqhc/mzac066 [DOI] [PubMed] [Google Scholar]
- 13. de León EA, Shriwise A, Gö T et al. Beyond building back better: imagining a future for human and planetary health. Lancet Planet Health. 2021;5:e827–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Tarrass F, Benjelloun M, Piccoli GB. Hemodialysis water reuse within a circular economy approach. What can we add to current knowledge? A point of view. J Nephrol. 2024;37:1801–5. 10.1007/s40620-024-01989-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Erickson KF, Sirich TL. Economic considerations of incremental hemodialysis. Kidney360. 2025;6:854–6. 10.34067/KID.0000000812 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Rydzewska-Rosołowska A, Głowińska I, Kakareko K et al. How low can we go with the dialysate flow? A retrospective study on the safety and adequacy of a water-saving dialysis prescription. Clin Kidney J. 2024;17:sfae238. PMID: 39421239. 10.1093/ckj/sfae238 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Beige J, Knöller S, Pachmann M et al. A website calculator to benchmark the carbon footprint of haemodialysis. Nephrol Dial Transplant. 2026. 10.1093/ndt/gfaf263 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Jiménez MDA, Audije-Gil J, Martínez R et al. How to improve the environmental impact in haemodialysis: small actions, big changes. Clin Kidney J. 2024;18:sfae407. 10.1093/ckj/sfae407 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Bonnet C, Torreggiani M, Bianco L et al. Autopsy of a hemodialysis machine: potential for recycling at the end of the life cycle. J Am Soc Nephrol. 2025;36:1126–37. PMID: 39671255. 10.1681/ASN.0000000584 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Caton E, Sharma S, Vilar E et al. Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023;38:435–46. 10.1093/ndt/gfac274 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Choo SMY, Murcutt G, Steinbach I et al. Sustainable health care in a renal centre—carbon saving is coupled with cost-efficiency. J Nephrol. 2025;38:2321–31. 10.1007/s40620-025-02354-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Nardelli L, Scalamogna A, Alfieri C et al. Incremental peritoneal dialysis: less is more-for the patient and the planet. Front Med. 2025;12:1676396. 10.3389/fmed.2025.1676396 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Murea M, Torreggiani M, Deira J et al. From niche to norm: a multiaction plan to close gaps and mainstream incremental hemodialysis. Kidney Int. 2025;108:201–13. PMID: 40403930. 10.1016/j.kint.2025.03.032 [DOI] [PubMed] [Google Scholar]
- 24. Torreggiani M, Fois A, Chatrenet A et al. Incremental and personalized hemodialysis start: a new standard of care. Kidney Int Rep. 2022;7:1049–61. PMID: 35571001. 10.1016/j.ekir.2022.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Ortiz A, JM Arreola Guerra, Chan JCN et al. ; Conference Participants. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;108:555–71. 10.1016/j.kint.2025.04.005 CrossRef]. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Shah AD, Goldfarb DS. Hemodiafiltration: balancing clinical efficacy with planetary health. Curr Opin Nephrol Hypertens. 2026;35:254–61. 10.1097/MNH.0000000000001160 [DOI] [PubMed] [Google Scholar]
- 27. Canaud B, Gagel A, Peters A et al. Does online high-volume hemodiafiltration offer greater efficiency and sustainability compared with high-flux hemodialysis? A detailed simulation analysis anchored in real-world data. Clin Kidney J. 2024;17:sfae147. 10.1093/ckj/sfae147 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Liyanage T, Ninomiya T, Jha V et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–82. PMID: 25777665. 10.1016/S0140-6736(14)61601-9 [DOI] [PubMed] [Google Scholar]
- 29. GBD 2023 Kidney Failure with Replacement Therapy Collaborators. Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Glob Health. 2025;13:e1378–95. 10.1016/S2214-109X(25)00198-6 [DOI] [PubMed] [Google Scholar]
- 30. Mortimer F, Isherwood J, Wilkinson A et al. Sustainability in quality improvement: redefining value. Future Healthc J. 2018;5:88–93. PMID: 31098540. 10.7861/futurehosp.5-2-88 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Connor A, Mortimer F, Tomson C. Clinical transformation: the key to green nephrology. Nephron Clin Pract. 2010;116:c200–6. 10.1159/000317200 [DOI] [PubMed] [Google Scholar]
- 32. van Vredendaal OP, Bé A, de Barbieri I et al. 2023 European Kidney Forum: the future of kidney care—investing in green nephrology to meet the European Green Deal targets. J Nephrol. 2025;38:815–25. 10.1007/s40620-025-02280-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Lok CE, Huber TS, Orchanian-Cheff A et al. Arteriovenous access for hemodialysis: a review. JAMA. 2024;331:1307–17. 10.1001/jama.2024.0535 [DOI] [PubMed] [Google Scholar]
- 34. Ravani P, Palmer SC, Oliver MJ et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol. 2013;24:465–73. 10.1681/ASN.2012070643 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Chua ALB, Amin R, Zhang J et al. The environmental impact of interventional radiology: an evaluation of greenhouse gas emissions from an academic interventional radiology practice. J Vasc Interv Radiol. 2021; 32:907–15.e3. 10.1016/j.jvir.2021.03.531 [DOI] [PubMed] [Google Scholar]
- 36. Alizada U, Sauleau E-A, Krummel T et al. Effect of emergency start and central venous catheter on outcomes in incident hemodialysis patients: a prospective observational cohort. J Nephrol. 2022;35:977–88. 10.1007/s40620-021-01188-7 [DOI] [PubMed] [Google Scholar]
- 37. Gokoel SRM, Gombert-Handoko KB, Zwart TC et al. Medication non-adherence after kidney transplantation: a critical appraisal and systematic review. Transplant Rev. 2020; 34:100511. PMID: 31627978. 10.1016/j.trre.2019.100511 [DOI] [PubMed] [Google Scholar]
- 38. Mitch WE, Remuzzi G. Diets for patients with chronic kidney disease, still worth prescribing. J Am Soc Nephrol. 2004;15:234–7. PMID: 14694178. 10.1097/01.ASN.0000106014.20274.C7 [DOI] [PubMed] [Google Scholar]
- 39. Carrero JJ, St-Jules DE, Biruete A et al. Quality-oriented diet therapy for chronic kidney disease. Nat Rev Nephrol. 2026;22:252–64. PMID: 41491876. 10.1038/s41581-025-01034-0 [DOI] [PubMed] [Google Scholar]
- 40. Ikizler TA, Burrowes JD, Byham-Gray LD et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76:S1–107. PMID: 32829751. 10.1053/j.ajkd.2020.05.006 [DOI] [PubMed] [Google Scholar]
- 41. Chiu YW, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4:1089–96. 10.2215/CJN.00290109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Shimoda H, Taniguchi M, Yamamoto S et al. Estimating the impact of pill burden on health utilities in hemodialysis therapy. Sci Rep. 2025;15:35315. 10.1038/s41598-025-19346-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Levey AS, Greene T, Beck GJ et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999;10:2426–39. 10.1681/ASN.V10112426 [DOI] [PubMed] [Google Scholar]
- 44. Tesfaye WH, McKercher C, Peterson GM et al. Medication adherence, burden and health-related quality of life in adults with predialysis chronic kidney disease: a prospective cohort study. Int J Environ Res Public Health. 2020;17:371. 10.3390/ijerph17010371 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Molnar AO, Bota S, Jeyakumar N et al. Potentially inappropriate prescribing in older adults with advanced chronic kidney disease. PLoS One. 2020;15:e0237868. 10.1371/journal.pone.0237868 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Tesfaye WH, Peterson GM, Castelino RL et al. Medication regimen complexity and hospital readmission in older adults with chronic kidney disease. Ann Pharmacother. 2019;53:28–34. 10.1177/1060028018793419 [DOI] [PubMed] [Google Scholar]
- 47. Chock YL, Wee YL, Gan SL et al. How willing are patients or their caregivers to deprescribe: a systematic review and meta-analysis. J Gen Intern Med. 2021;36:3830–40. 10.1007/s11606-021-06965-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. O’Mahony D, O’Sullivan D, Byrne S et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Mortimer F. The sustainable physician. Clin Med. 2010;10:110–1. 10.7861/clinmedicine.10-2-110 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Neves AL, Freise L, Laranjo L et al. Impact of providing patients access to electronic health records on quality and safety of care: a systematic review and meta-analysis. BMJ Qual Saf. 2020;29:1019–32. 10.1136/bmjqs-2019-010581 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Arora P, Obrador GT, Ruthazer R et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol. 1999;10:1281–6. 10.1681/ASN.V1061281 [DOI] [PubMed] [Google Scholar]
- 52. Flagg ME, Bhandari SK, Pak KJ et al. Dialysis transition patterns of chronic kidney disease patients with and without heart failure. Mayo Clin Proc. 2025;100:970–81. 10.1016/j.mayocp.2024.11.029 [DOI] [PubMed] [Google Scholar]
- 53. Cheng L, Hu N, Song D et al. Early versus late nephrology referral and patient outcomes in chronic kidney disease: an updated systematic review and meta-analysis. BMC Nephrol. 2025;26:25. 10.1186/s12882-025-03944-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Smart NA, Titus TT Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011;124:1073–80.e2. 10.1016/j.amjmed.2011.04.026 [DOI] [PubMed] [Google Scholar]
- 55. Obrador GT, Ruthazer R, Arora P et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10:1793–800. 10.1681/ASN.V1081793 [DOI] [PubMed] [Google Scholar]
- 56. World Health Organisation . Reducing the Burden of Noncommunicable Diseases through Promotion of Kidney Health and Strengthening Prevention and Control of Kidney Disease [Internet]. https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R6-en.pdf (13 February 2026, date last accessed). [Google Scholar]
- 57. Piccoli GB, Garcia-Garcia G, Salomone M et al. Many strategies enabling us to optimize kidney care may also be planet friendly. Kidney Int. 2025;107:628–39. PMID: 39862970. 10.1016/j.kint.2024.08.040 [DOI] [PubMed] [Google Scholar]
- 58. Piccoli GB. Humanities in nephrology: in defence of time in our medical profession. J Nephrol. 2024;37:839–40. 10.1007/s40620-024-02003-9 [DOI] [PubMed] [Google Scholar]
- 59. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117–314. PMID: 38490803. 10.1016/j.kint.2023.10.018 [DOI] [PubMed] [Google Scholar]
- 60. Oliva-Damaso N, Delanaye P, Oliva-Damaso E et al. Risk-based versus GFR threshold criteria for nephrology referral in chronic kidney disease. Clin Kidney J. 2022;15:1996–2005. 10.1093/ckj/sfac104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Kelly JT, Gonzalez-Ortiz A, St-Jules DE et al. Animal protein intake and possible cardiovascular risk in people with chronic kidney disease: mechanisms and evidence. Adv Kidney Dis Health. 2023;30:480–6. PMID: 38453263. 10.1053/j.akdh.2023.06.003 [DOI] [PubMed] [Google Scholar]
- 62. Tucker AC, Martínez-Steele E, Caulfield LE et al. What is “healthy” food? A cross-sectional evaluation of foods and beverages consumed by United States adults that satisfy the United States Food and Drug Administration’s updated “healthy” claim criteria. Am J Clin Nutr. 2026;123:101121. PMID: 41309038. 10.1016/j.ajcnut.2025.11.011/bib></bib> [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Kim H, Caulfield LE, Garcia-Larsen V et al. Plant-based diets are associated with a lower risk of incident cardiovascular disease, cardiovascular disease mortality, and all-cause mortality in a general population of middle-aged adults. J Am Heart Assoc. 2019;8:e012865. PMID: 31387433. 10.1161/JAHA.119.012865 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Alvarez-Elias AC, Brenner BM, Luyckx VA. Climate change and its influence in nephron mass. Curr Opin Nephrol Hypertens. 2024;33:102–9. 10.1097/MNH.0000000000000932 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Garg RK. The alarming rise of lifestyle diseases and their impact on public health: a comprehensive overview and strategies for overcoming the epidemic. J Res Med Sci. 2025;30:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. GBD 2021 Adult BMI Collaborators . Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405:813–38. PMID. 10.1016/S0140-6736(25)00355-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Diabetes care and research in Europe: the Saint Vincent declaration. Diabet Med. 1990;7:360. 10.1111/j.1464-5491.1990.tb01405.x [DOI] [PubMed] [Google Scholar]
- 68. Piwernetz K, Home PD, Snorgaard O et al. ; The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. Diabet Med. 1993;10:371–7. 10.1111/j.1464-5491.1993.tb00083.x [DOI] [PubMed] [Google Scholar]
- 69. Peired AJ, Laranjinha I, Demirtas G et al. An urgent call for environmental accountability in nephrology clinical trials. Clin Kidney J. 2024;17:sfae181. 10.1093/ckj/sfae181 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. De Chiara L, Ronco P, Rovin BH. Green nephrology: an editor’s journey. J Nephrol. 2024;37:3–5. 10.1007/s40620-024-01890-2 [DOI] [PubMed] [Google Scholar]
- 71. Durgan J, Rodríguez-Martínez M, Rouse B. Green Labs: a guide to developing sustainable science in your organization. Immunol Cell Biol. 2023;101:289–301. 10.1111/imcb.12624 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Greever C, Ramirez-Aguilar K, Connelly J. Connections between laboratory research and climate change: what scientists and policy makers can do to reduce environmental impacts. FEBS Lett. 2020;594:3079–85. 10.1002/1873-3468.13932 [DOI] [PubMed] [Google Scholar]
- 73. Ambulos NP, Mische SM, Fox JW. Greater reliance on shared resources can enrich the future success of academic research. J Biomol Tech. 2025;36:3fc1f5fe.e2548884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. National Institute for Health and Care Research . NIHR Carbon Reduction Guidelines. https://www.nihr.ac.uk/about-us/what-we-do/key-initiatives/climate-health-sustainability/carbon-reduction-guidelines (15 February 2026, date last accessed).
- 75. Hoffmann JM, Bauer A, Grossmann R. The carbon footprint of clinical trials: a global survey on the status quo and current regulatory guidance. BMJ Glob Health. 2023;8:e012754. 10.1136/bmjgh-2023-012754 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Quann N, Burns S, Hull KL et al. Reducing the carbon footprint of research: experience from the NightLife study. BMJ Open. 2023;13:e070200. 10.1136/bmjopen-2022-070200 [DOI] [PMC free article] [PubMed] [Google Scholar]





